A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Clinical trial NCT05852691 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05852691
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-18
- Primary completion
- 2026-10-31
- Enrollment
- 83
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.